Wong MK - Search Results

1

Crosslinked multilamellar liposomes for controlled delivery of anticancer drugs.

Joo KI, Xiao L, Liu S, Liu Y, Lee CL, Conti PS, Wong MK, Li Z, Wang P. Joo KI, et al. Among authors: wong mk. Biomaterials. 2013 Apr;34(12):3098-109. doi: 10.1016/j.biomaterials.2013.01.039. Epub 2013 Jan 30. Biomaterials. 2013. PMID: 23375392 Free PMC article.

2

Enhanced therapeutic efficacy of iRGD-conjugated crosslinked multilayer liposomes for drug delivery.

Liu Y, Ji M, Wong MK, Joo KI, Wang P. Liu Y, et al. Among authors: wong mk. Biomed Res Int. 2013;2013:378380. doi: 10.1155/2013/378380. Epub 2013 Apr 15. Biomed Res Int. 2013. PMID: 23691500 Free PMC article.

3

Codelivery of doxorubicin and paclitaxel by cross-linked multilamellar liposome enables synergistic antitumor activity.

Liu Y, Fang J, Kim YJ, Wong MK, Wang P. Liu Y, et al. Among authors: wong mk. Mol Pharm. 2014 May 5;11(5):1651-61. doi: 10.1021/mp5000373. Epub 2014 Apr 7. Mol Pharm. 2014. PMID: 24673622 Free PMC article.

4

Codelivery of chemotherapeutics via crosslinked multilamellar liposomal vesicles to overcome multidrug resistance in tumor.

Liu Y, Fang J, Joo KI, Wong MK, Wang P. Liu Y, et al. Among authors: wong mk. PLoS One. 2014 Oct 17;9(10):e110611. doi: 10.1371/journal.pone.0110611. eCollection 2014. PLoS One. 2014. PMID: 25330237 Free PMC article.

5

Weighing the evidence for immune therapy and targeted therapy in renal cancer and melanoma.

Dorff TB, Wong MK. Dorff TB, et al. Among authors: wong mk. Oncology (Williston Park). 2013 Jul;27(7):691-2, 694. Oncology (Williston Park). 2013. PMID: 23977764 Free article. No abstract available.

6

Patients rank toxicity against progression free survival in second-line treatment of advanced renal cell carcinoma.

Wong MK, Mohamed AF, Hauber AB, Yang JC, Liu Z, Rogerio J, Garay CA. Wong MK, et al. J Med Econ. 2012;15(6):1139-48. doi: 10.3111/13696998.2012.708689. Epub 2012 Jul 18. J Med Econ. 2012. PMID: 22808923 Free article.

7

Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United States.

Wong MK, Jonasch E, Pal SK, Signorovitch JE, Lin PL, Wang X, Liu Z, Culver K, Scott JA, George DJ, Vogelzang NJ. Wong MK, et al. Expert Opin Pharmacother. 2015 Apr;16(6):805-19. doi: 10.1517/14656566.2015.1020298. Epub 2015 Mar 12. Expert Opin Pharmacother. 2015. PMID: 25766864

8

Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review.

Wong MK, Yang H, Signorovitch JE, Wang X, Liu Z, Liu NS, Qi CZ, George DJ. Wong MK, et al. Curr Med Res Opin. 2014 Apr;30(4):537-45. doi: 10.1185/03007995.2013.871243. Epub 2013 Dec 17. Curr Med Res Opin. 2014. PMID: 24329572

9

Suppression of Langerhans cell activation is conserved amongst human papillomavirus α and β genotypes, but not a µ genotype.

Da Silva DM, Movius CA, Raff AB, Brand HE, Skeate JG, Wong MK, Kast WM. Da Silva DM, et al. Among authors: wong mk. Virology. 2014 Mar;452-453:279-86. doi: 10.1016/j.virol.2014.01.031. Epub 2014 Feb 17. Virology. 2014. PMID: 24606705 Free PMC article.

10

Inhibition of Langerhans cell maturation by human papillomavirus type 16: a novel role for the annexin A2 heterotetramer in immune suppression.

Woodham AW, Raff AB, Raff LM, Da Silva DM, Yan L, Skeate JG, Wong MK, Lin YG, Kast WM. Woodham AW, et al. Among authors: wong mk. J Immunol. 2014 May 15;192(10):4748-57. doi: 10.4049/jimmunol.1303190. Epub 2014 Apr 9. J Immunol. 2014. PMID: 24719459 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

619 results

Search Page